Israeli Drug-Free Migraine Device Secures $45M
Digital therapeutics company Theranica has received $45 million in its Series C funding round towards the commercial expansion of its drug-free migraine treatment, Nerivio, in the US.
Newsrael News Desk 31.08.2022
Nerivio is a drug-free, smartphone-controlled wearable device for the treatment of episodic and chronic migraine in people aged 12 and older.
Philadelphia-based New Rhein Healthcare Investors led the round, with participation of existing investors aMoon, Lightspeed Venture Partners, LionBird, Takoa Invest, and Corundum Open Innovation.
“In spite of several decades of new medications, millions of individuals still suffer from frequent debilitating migraine headaches,” said Alon Ironi.
Source: Nocamels
Did you find this article interesting?